Anna Grundy

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The use of cell lines or animal models has significant disadvantages when dealing with a set of heterogeneous diseases such as epithelial ovarian cancer. This has clinical relevance in that biomarkers developed using cell line or animal models are often not transferable to the clinical setting. In this study, we describe the development of a robust protocol(More)
  • 1